China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026)
China Pharma Holdings (CPHI) posted Current Deferred Revenue of $61746.0 for Q1 2026, down 44.66% on a QoQ basis from $111580.0 in Q4 2025, and down 46.04% year-over-year from $114435.0 in Q1 2025.
China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026) Analysis & Trends
China Pharma Holdings' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $61746.0 for Q1 2026.
- Quarterly Current Deferred Revenue fell 46.04% year-over-year to $61746.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61746.0 (down 46.04% YoY) and the FY2025 annual result came in at $111580.0, down 31.21% from the prior year.
- Current Deferred Revenue was $61746.0 for Q1 2026 at China Pharma Holdings, down from $111580.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $520295.0 in Q4 2022 and bottomed at $24920.0 in Q3 2024.
- A 5-year average of $130953.5 and a median of $112357.0 in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 85.52% — and 2025, when it soared 385.2%.
- China Pharma Holdings' Current Deferred Revenue stood at $520295.0 in 2022, then tumbled by 82.6% to $90507.0 in 2023, then jumped by 79.22% to $162208.0 in 2024, then plunged by 31.21% to $111580.0 in 2025, then slumped by 44.66% to $61746.0 in 2026.
- Business Quant data shows CPHI's Current Deferred Revenue at $61746.0 in Q1 2026, $111580.0 in Q4 2025, and $120912.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,746.00 |
| Dec 31, 2025 | 111,580.00 |
| Sep 30, 2025 | 120,912.00 |
| Jun 30, 2025 | 77,683.00 |
| Mar 31, 2025 | 114,435.00 |
| Dec 31, 2024 | 162,208.00 |
| Sep 30, 2024 | 24,920.00 |
| Jun 30, 2024 | 101,056.00 |
| Mar 31, 2024 | 112,357.00 |
| Dec 31, 2023 | 90,507.00 |
| Sep 30, 2023 | 172,110.00 |
| Jun 30, 2023 | 61,334.00 |
| Mar 31, 2023 | 136,681.00 |
| Dec 31, 2022 | 520,295.00 |
| Sep 30, 2022 | 84,048.00 |
| Jun 30, 2022 | 138,238.00 |
| Mar 31, 2022 | 136,099.00 |
| Dec 31, 2021 | 210,028.00 |
| Sep 30, 2021 | 420,039.00 |
| Jun 30, 2021 | 525,579.00 |